Unknown

Dataset Information

0

Recent advances in understanding and treating vasculitis.


ABSTRACT: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.

SUBMITTER: Koster MJ 

PROVIDER: S-EPMC4916989 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recent advances in understanding and treating vasculitis.

Koster Matthew J MJ   Warrington Kenneth J KJ  

F1000Research 20160620


Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dos  ...[more]

Similar Datasets

| S-EPMC8009191 | biostudies-literature
| S-EPMC7539078 | biostudies-literature
| S-EPMC6053698 | biostudies-literature
| S-EPMC6117860 | biostudies-literature
| S-EPMC5420084 | biostudies-literature
| S-EPMC7531047 | biostudies-literature
| S-EPMC5357034 | biostudies-other
| S-EPMC5017284 | biostudies-other
| S-EPMC7886064 | biostudies-literature
| S-EPMC4795442 | biostudies-literature